Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 12/20 | 0.45 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12649821 | 0.87 | MAP2K1 (0.41) | MAP2K1MAP2K2GAAMAPTTHRB | |
| SCHEMBL1774323 | 0.87 | MAP2K1 (0.56) | MAP2K1MAP2K2 | |
| SCHEMBL719657 | 0.75 | DGAT1 (0.54) | GABRA1GABRB1GABRA3GABRB2PTGES | |
| SCHEMBL1775941 | 0.75 | MAP2K1 (0.54) | MAP2K1MAP2K2 | |
| Hydrochloric Acid SCHEMBL31426389 | 0.74 | DGAT1 (0.53) | GABRA1GABRB1GABRA3GABRB2PTGES | |
| SCHEMBL392036 | 0.72 | MAP2K1 (0.45) | MAP2K1MAP2K2GAAALDH1A1NPC1 | |
| SCHEMBL5559374 | 0.72 | MAP2K1 (0.41) | MAP2K1MAP2K2GAAMAPTALDH1A1 | |
| SCHEMBL5623989 | 0.72 | MAP2K1 (0.49) | MAP2K1MAP2K2GAAMAPTTHRB | |
| SCHEMBL5623781 | 0.72 | MAP2K1 (0.77) | MAP2K1MAP2K2 | |
| SCHEMBL4789851 | 0.71 | MAP2K1 (0.46) | MAP2K1MAP2K2PTGESALOX5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943659-B2 | cancerous hyperproliferative disorders; 5-Acetyl-2-(2-fluoro-4-iodo-phenylamino)-1H-pyrrole-3-carboxylic acid; 2-acetyl-5-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-imidazole-4-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943659-B2 | cancerous hyperproliferative disorders; 5-Acetyl-2-(2-fluoro-4-iodo-phenylamino)-1H-pyrrole-3-carboxylic acid; 2-acetyl-5-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-imidazole-4-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| EP-2113500-A1 | MAPK/ERK kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2009-11-04 | — | — | EP | disclosed |
| EP-2089359-A2 | MAPK/ERK KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2009-08-19 | — | — | EP | disclosed |
| US-20080188453-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA CALIFORNIA, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188453-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA CALIFORNIA, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008055236-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008055236-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188453-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | MAP2K1 44/4885MAP2K2 43/4885GABRA1 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.